Education
About Us
Working with TipRanks
Follow Us
Satellos Bioscience (TSE:MSCL)
TSX:MSCL
MSCL Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.38 - C$1.32
Previous CloseN/A
Volume29.01K
Average Volume (3M)230.81K
Market Cap
$136.50M
Enterprise ValueC$28.57M
Total Cash (Recent Filing)C$1.92M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Mar 27, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding153,375,400
10 Day Avg. Volume141,153
30 Day Avg. Volume230,806
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.25Price Target Upside35.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Satellos Bioscience News
PremiumCompany Announcements
Satellos Bioscience to Present Phase 1 Data for SAT-3247 at MDA Conference
PremiumCompany Announcements
Satellos Completes Phase 1 Enrollment for DMD Drug Trial
PremiumCompany Announcements
Satellos Bioscience to Showcase at Oppenheimer Healthcare Conference
PremiumCompany Announcements
Satellos Bioscience Secures $40 Million Funding Boost
PremiumCompany Announcements
Satellos Bioscience Announces Public Offering of Shares
PremiumCompany Announcements
Satellos Advances in Duchenne Muscular Dystrophy Trial
PremiumCompany Announcements
Satellos Bioscience Joins Rare Disease Summit---
Bulls Say, Bears Say
Bulls Say
Clinical Trials ProgressSatellos is steadily advancing its ongoing Phase 1 study evaluating SAT-3247’s safety and pharmacokinetics in healthy volunteers.
Safety ProfileNo drug-related adverse events have been reported to date in the Phase 1 study of SAT-3247.
Bears Say
Risks And ChallengesRisks identified include clinical, regulatory, commercial, competition, and dilution.
---
Options Prices
Currently, No data available
---
Ownership Overview
MSCL FAQ
What was Satellos Bioscience’s price range in the past 12 months?
Satellos Bioscience lowest stock price was C$0.38 and its highest was C$1.32 in the past 12 months.
What is Satellos Bioscience’s market cap?
Satellos Bioscience’s market cap is $136.50M.
When is Satellos Bioscience’s upcoming earnings report date?
Satellos Bioscience’s upcoming earnings report date is Mar 27, 2025 which is in 13 days.
How were Satellos Bioscience’s earnings last quarter?
Satellos Bioscience released its earnings results on Nov 13, 2024. The company reported -C$0.08 earnings per share for the quarter, missing the consensus estimate of -C$0.05 by -C$0.03.
Is Satellos Bioscience overvalued?
According to Wall Street analysts Satellos Bioscience’s price is currently Undervalued.
Does Satellos Bioscience pay dividends?
Satellos Bioscience does not currently pay dividends.
What is Satellos Bioscience’s EPS estimate?
Satellos Bioscience’s EPS estimate is -0.04.
How many shares outstanding does Satellos Bioscience have?
Satellos Bioscience has 153,375,400 shares outstanding.
What happened to Satellos Bioscience’s price movement after its last earnings report?
Satellos Bioscience reported an EPS of -C$0.08 in its last earnings report, missing expectations of -C$0.05. Following the earnings report the stock price went up 1.19%.
Which hedge fund is a major shareholder of Satellos Bioscience?
Currently, no hedge funds are holding shares in TSE:MSCL
---
Satellos Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$1.25 (35.90% Upside)
C$1.25 (35.90% Upside)
Insider Transactions
Bought Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.60%
12-Months-Change
Fundamentals
Return on Equity
-84.66%
Trailing 12-Months
Asset Growth
-50.23%
Trailing 12-Months
Company Description
Satellos Bioscience
Satellos Bioscience (MSCL) is a biotechnology company focused on the development of novel therapeutic solutions aimed at muscle regeneration and repair. The company operates within the life sciences sector and leverages advanced scientific research to address degenerative muscle diseases. Satellos' core product offerings include proprietary drug candidates designed to stimulate and enhance muscle regeneration processes, potentially transforming the treatment landscape for conditions such as Duchenne Muscular Dystrophy.
---
MSCL Stock 12 Month Forecast
Average Price Target
C$1.25
▲(35.90% Upside)
Technical Analysis
Best Analysts Covering MSCL
1 Year
1 Year Success Rate
6/6 ratings generated profit
1 Year Average Return
+53.12%
reiterated a buy rating 4 months ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +53.12% per trade.
---